Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in Dementia (OBAD) - An Eight Week Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi Center Trial. A Phase III Study

NCT00145691 is registered in ClinicalTrials.gov with Sykehuset Innlandet HF as lead sponsor.

NCT NCT00145691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00145691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in Dementia (OBAD) - An Eight Week Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi Center Trial. A Phase III Study
Lead sponsor
Sykehuset Innlandet HF
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2005
Completion date
October 31, 2006
Enrollment
100
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

agitation aggression in dementia